Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Flawed Clinical Research in the Media Leads to Unnecessary Hysteria Says Researchers

By BOSTON UNIVERSITY MEDICAL CENTER | December 9, 2016

Collaboration between media and medical journals often leads to misinformation and hysteria.

When flawed clinical research is reported in the media with hype and sensationalism, it has the potential to have a devastating effect on patients, physicians, the scientific community and eventually society as a whole.

In a review article in the journal EMBO Reports, the authors question how controversial and weak studies are publicized by the media and often coupled with a narrative that is either false or with little scientific basis. The blame for misleading the public, they believe, should be shouldered equally by journalists, scientists, journal editors and research institutions.

As an example, the authors describe the changes in medical attitudes and practices regarding the use of hormone replacement therapy (HRT) in peri- and post-menopausal women following intense coverage of the Women’s Health Initiative study. In 2002, the media reported that this large study had been prematurely halted after it showed greater risks of stroke, death and invasive breast cancer for women who took estrogen and progesterone compared with those who received placebo. Physicians called for immediate curtailment of HRT use in women and prescriptions fell by more than 80 percent and remained at that level for years. Today, healthcare experts still routinely reference this study as demonstrating the dangers of HRT despite the fact that a 2013 follow-up study reported no significant difference between HRT and placebo for mortality or a long list of other adverse events.

“We believe that the collaboration between media and scientific journals in communicating advances in science and medicine to the public may result in misinformation and distortion. Unfortunately, this collaboration often exaggerates and allows bad science to be disseminated and shared. Media is often drawn to these controversial studies and they promote them with a narrative that is difficult to change even if it is wrong,” explains lead author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at Boston University School of Medicine. Traish and his colleagues believe a number of strategies could help prevent medical professionals and the general public from accepting distorted study results and their coverage in the media, including recognizing the collaboration between medical journals; being wary of pronouncements from individuals who are unlikely to have clinical experience with a drug or treatment and recognizing the limitations of any one study since as many as 70 percent of the most highly cited studies eventually prove to be unreproducible.

Traish believes this critical analysis of how the media and medical journals promote questionable studies is of critical importance to the public, academics, policy makers and research institutions. “This is an issue that needs to be discussed, debated and taught to our medical students to be prepared to enter the real world of medicine and its complexities.”

(Source: EurekAlert)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE